Abstract
Cholinesterase inhibitors (ChEIs), the mainstay treatment for dementia, have systemic actions that can affect cardiovascular and autonomic nervous system (ANS). Thirty-nine patients with Alzheimer´s disease or mixed dementia underwent a comprehensive clinical evaluation, prior to and during ChEIs therapy, including orthostatic challenge, electrocardiogram (EKG) and heart rate variability (HRV) spectral analysis through Holter recordings. ChEIs therapy determined a decrease in supine diastolic blood pressure (BP) and in both diastolic and systolic BP in orthostatic position (79.8 ± 9.0 vs. 76.4 ± 9.3 mmHg, p=0.012; 79.9 ± 11.6 vs. 75.3 ± 9.9, p=0.005 and 144.6 ± 25.8 vs. 137.6 ± 21.1, p=0.020, respectively). Spectral analysis revealed no difference on static HRV components, but, during orthostatic challenge, an increase in LF/HF ratio (2.2±2.4 vs. 4.6±5.9, p=0.011) and a reduction in HF component emerged (1604.3 ± 5610.1 vs. 266.1 ± 525.5, p=0.010). ChEIs showed no influence on EKG parameters or on the occurrence of orthostatic hypotension. Treatment with ChEIs was associated with functional improvement of the ANS behavior and to a decrease in supine DBP and in both orthostatic SBP and DBP.
Keywords: Dementia, cholinesterase inhibitors, holter monitoring, orthostatic hypotension, electrocardiogram.
Current Alzheimer Research
Title:Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Volume: 10 Issue: 5
Author(s): Filipi Leles da Costa Dias, Rose Mary Ferreira Lisboa da Silva, Edgar Nunes de Moraes and Paulo Caramelli
Affiliation:
Keywords: Dementia, cholinesterase inhibitors, holter monitoring, orthostatic hypotension, electrocardiogram.
Abstract: Cholinesterase inhibitors (ChEIs), the mainstay treatment for dementia, have systemic actions that can affect cardiovascular and autonomic nervous system (ANS). Thirty-nine patients with Alzheimer´s disease or mixed dementia underwent a comprehensive clinical evaluation, prior to and during ChEIs therapy, including orthostatic challenge, electrocardiogram (EKG) and heart rate variability (HRV) spectral analysis through Holter recordings. ChEIs therapy determined a decrease in supine diastolic blood pressure (BP) and in both diastolic and systolic BP in orthostatic position (79.8 ± 9.0 vs. 76.4 ± 9.3 mmHg, p=0.012; 79.9 ± 11.6 vs. 75.3 ± 9.9, p=0.005 and 144.6 ± 25.8 vs. 137.6 ± 21.1, p=0.020, respectively). Spectral analysis revealed no difference on static HRV components, but, during orthostatic challenge, an increase in LF/HF ratio (2.2±2.4 vs. 4.6±5.9, p=0.011) and a reduction in HF component emerged (1604.3 ± 5610.1 vs. 266.1 ± 525.5, p=0.010). ChEIs showed no influence on EKG parameters or on the occurrence of orthostatic hypotension. Treatment with ChEIs was associated with functional improvement of the ANS behavior and to a decrease in supine DBP and in both orthostatic SBP and DBP.
Export Options
About this article
Cite this article as:
Dias Filipi Leles da Costa, Silva Rose Mary Ferreira Lisboa da, Moraes Edgar Nunes de and Caramelli Paulo, Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia, Current Alzheimer Research 2013; 10 (5) . https://dx.doi.org/10.2174/1567205011310050003
DOI https://dx.doi.org/10.2174/1567205011310050003 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Cystatin C-A Useful Endogenous Marker of Renal Function in Intensive Care Unit Patients at Risk for or with Acute Renal Failure?
Current Medicinal Chemistry Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design Prolonged Physiologic Doses of Corticosteroids for the Treatment of Severe Community Acquired Pneumonia
Current Respiratory Medicine Reviews Hypertension in Pregnancy: Clinical Manifestations and Treatment
Current Hypertension Reviews Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety New 1,3-oxazolylphosphonium Salts as Potential Biocides: QSAR Study, Synthesis, Antibacterial Activity and Toxicity Evaluation
Letters in Drug Design & Discovery A Review of the Ethnopharmacology, Phytochemistry and Pharmacology of Plants of the Maytenus Genus
Current Pharmaceutical Design Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews Environmental Toxicants as Extrinsic Epigenetic Factors for Parkinsonism: Studies Employing Transgenic C. elegans Model
CNS & Neurological Disorders - Drug Targets Near Infrared Spectroscopy in Healthy Preterm and Term Newborns: Correlation with Gestational Age and Standard Monitoring Parameters
Current Neurovascular Research Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling
Current Medicinal Chemistry From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued)